Publication AWA

In the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification has published the Analyses for Verification (AWA) for the evaluation of reimbursement applications:

• Jardiance, empagliflozin for the treatment of type 2 diabetes mellitus,
• Jardiance, empagliflozin for the treatment of chronic renal failure,
• Jardiance, empagliflozin in the treatment of heart failure,
• Talzenna, talazoparib for the treatment of prostate cancer.

The Agency’s verification analyses, along with the applicant’s analyses, are available on AOTMiT’s BIP – click here.

We encourage you to read the full documents and submit your comments within the prescribed period of 7 days from the date of publication.

We plan to publish the following AWA next week:

• Lokelma, sodium zirconium cyclosilicate for the treatment of hyperkalemia in chronic renal disease in drug program B.6. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”